| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Adolor: Is There Anything Left?
Posted on 11/02/2007 11:34:40 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
Adolor Corp. (ADLR-NASDAQ) may have just joined the ranks of current and future biotech zombies. The company suspended its lead new drug candidate for potential treatment of opioid-induced bowel dysfunction.
Safety concerns prompted the halt after increased risk of heart attacks and other cardiovascular events were witnessed. The company said the data will be further analyzed, but this follows some FDA action requests in November. Per our closing remarks on November 7, 2006: Adolor (ADLR) fell another 5.2% to $7.29 the day after the FDA requested more data for its bowel disorder drug.
This one may have been foreseen, but you wouldn't know it by the stock price today. Shares are down 58% at $3.59, well under its previous 52-week lows. The prior 52-week trading range was $6.50 to $26.17. Ouch! Its new market cap is only $165 million compared to net current assets (12/31/06) $193.3 million and total liabilities of $47.4 million. It has had a cash burn rate of roughly $20 million after its partnership study fees.
Now it has to figure out what to do, and if the company decides to abandon the study after further reviews then it will have to scale down and go into survival mode. Here is the rest of its pipeline and R&D Structure.
Source: 247WallSt.com
_____________________
24/7 Wall St.
Adolor Corp. (ADLR-NASDAQ) may have just joined the ranks of current and future biotech zombies. The company suspended its lead new drug candidate for potential treatment of opioid-induced bowel dysfunction.
Safety concerns prompted the halt after increased risk of heart attacks and other cardiovascular events were witnessed. The company said the data will be further analyzed, but this follows some FDA action requests in November. Per our closing remarks on November 7, 2006: Adolor (ADLR) fell another 5.2% to $7.29 the day after the FDA requested more data for its bowel disorder drug.
This one may have been foreseen, but you wouldn't know it by the stock price today. Shares are down 58% at $3.59, well under its previous 52-week lows. The prior 52-week trading range was $6.50 to $26.17. Ouch! Its new market cap is only $165 million compared to net current assets (12/31/06) $193.3 million and total liabilities of $47.4 million. It has had a cash burn rate of roughly $20 million after its partnership study fees.
Now it has to figure out what to do, and if the company decides to abandon the study after further reviews then it will have to scale down and go into survival mode. Here is the rest of its pipeline and R&D Structure.
Source: 247WallSt.com
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
LearningMarkets.com - Fri Oct 03, 2008 03:14PM
Written by S. Wade Hansen Why Should You Care About O [read more]
Written by S. Wade Hansen Why Should You Care About O [read more]
<< My Home | TheMoneyBlogs Home